Loading...
NPI 1093139313 · Conshohocken, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Freedom Pathology Partners LLC is a clinical medical laboratory provider located in Conshohocken, Pennsylvania. This profile covers 21 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Freedom Pathology Partners LLC |
| Address | 524 E Elm St Ste A |
| City | Conshohocken |
| State | PA |
| ZIP | 19428 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 6, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.4M |
| Medicaid | $38.4K |
FREEDOM PATHOLOGY PARTNERS LLC is predominantly a Medicare-focused laboratory by scale: lifetime Medicare revenue is $7.4M compared with just $38.4K in Medicaid, indicating Medicare drives virtually all billed revenue for this NPI (enumerated 2014-02-06, ~12 years ago). The provider’s tenure since 2014-02-06 suggests an established presence, but its payer mix is effectively single-payer in economic importance.
Revenue is highly concentrated in a few molecular/NAAT assays on Medicare: the top three Medicare codes (87798, 87150, 87481) account for 84.7% of this provider’s total Medicare revenue, with 87798 at 39.8%, 87150 at 31.8%, and 87481 at 13.1%. That concentration means the lab’s financial profile is driven almost entirely by a small set of amplified nucleic acid probe tests.
The code mix indicates the business is a high-volume nucleic acid amplification testing (NAAT) lab focused on infectious-agent identification and organism characterization: dominant Medicare codes include 87798 (85.7K claims), 87150 (68.6K claims) and 87481 (28.2K claims), and related coded services for MRSA (87641), VRE (87500), Strep B (87653) and Staph aureus (87640) are also billed — consistent with a centralized molecular microbiology operation rather than a broad-spectrum hospital pathology service.
On national competitive standing for Medicare, this provider ranks well above typical volumes for multiple high-revenue codes: 87150 ranks #6 of 190 providers nationally (97th percentile) and 87481 ranks #15 of 1117 providers nationally (99th percentile) and is explicitly labeled an extreme outlier, while 87798 ranks #22 of 1319 (98th percentile). These placements indicate the lab is a major national volume player for several specific NAAT assays.
By contrast, the provider’s Medicaid positioning is modest within Pennsylvania: the top Medicaid codes follow the same pattern (87798, 87150, 87481) but ranks are mid-pack in-state (87798: #24 of 68, 66th percentile; 87150: #14 of 44, 70th percentile; 87481: #28 of 67, 59th percentile). The top three Medicaid codes account for 84.0% of the provider’s Medicaid revenue, but absolute Medicaid revenue ($38.4K) is minimal, so Medicaid does not materially move the business’s revenue profile.
Payment-per-claim patterns show low per-claim Medicare reimbursements paired with very high claim volumes: many primary Medicare NAAT codes have an average paid/claim of $34 (e.g., 87798, 87150, 87481), while select Medicare codes like 87801 average $69 and culture susceptibility 87184 averages $7. For Medicaid the average paid/claim is lower on comparable codes (87798 $31, 87150 $23, 87481 $9), underscoring that the lab’s revenue advantage is driven by Medicare volume more than higher per-test Medicaid rates.
Surgical pathology and anatomic pathology services are present but peripheral: 88305 appears on both payers at low volumes (Medicare 44 claims $36, Medicaid 36 claims $38) and immunohistochemistry codes such as 88342 (33 claims, $58) and 88341 (32 claims, $50) are negligible compared with NAAT claim counts. This pattern supports the interpretation that the provider’s core competency and revenue engine are molecular infectious-disease assays rather than diagnostic surgical pathology.
Operationally, the absolute claim volumes for top Medicare assays (e.g., 85.7K claims for 87798 and 68.6K claims for 87150) together with the fact that the top three Medicare codes compose 84.7% of Medicare revenue point to a centralized, high-throughput testing model that is highly dependent on a small set of assays; that concentration could make overall revenue sensitive to changes in utilization patterns or reimbursement policy for those specific codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 85,680 | $30 | $2.9M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 68,590 | $30 | $2.3M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 28,200 | $30 | $958.9K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 6,590 | $30 | $224.1K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 6,590 | $30 | $224K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 6,580 | $30 | $223.9K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 6,580 | $30 | $223.7K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 1,850 | $30 | $62.9K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 1,850 | $30 | $62.9K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 670 | $70 | $46K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 520 | $30 | $16.1K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 510 | $20 | $11.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 510 | $10 | $4.6K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 510 | $1 | $1.5K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 40 | $40 | $1.4K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 510 | $1 | $1K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 510 | $1 | $1K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 510 | $1 | $1K |
| 87184 | The lab analyst performs the technical steps to evaluate a culture isolate’s susceptibility, or sensitivity, to up to 12 specific antimicrobial agents, commonly called antibiotics, by placing disks… | 100 | $1 | $200 |
| 81000 | The lab analyst inserts a dip stick into a freshly collected urine specimen, removes the dip stick, and shakes off the excess urine. Alternatively, the analyst may place drops of the urine specimen… | 10 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 24 | 70 | 270 | $50 | $108.2K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 14 | 40 | 270 | $70 | $63.1K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 28 | 70 | 360 | $30 | $58.1K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 410 | 490 | 320 | $40 | $55.9K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 15 | 30 | 480 | $10 | $33.6K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 12 | 20 | 610 | $10 | $31.1K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 8 | 10 | 660 | $10 | $26.4K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 10 | 30 | 150 | $10 | $11.1K |
| 81000 | The lab analyst inserts a dip stick into a freshly collected urine specimen, removes the dip stick, and shakes off the excess urine. Alternatively, the analyst may place drops of the urine specimen… | 53 | 60 | 200 | $1 | $2.6K |
| 87184 | The lab analyst performs the technical steps to evaluate a culture isolate’s susceptibility, or sensitivity, to up to 12 specific antimicrobial agents, commonly called antibiotics, by placing disks… | 3 | 10 | 40 | $10 | $580 |
Other providers in the same ZIP code as Freedom Pathology Partners LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Lincoln Healthcare, LLC | PA | Home Health Agency | $0 | $37.3M |
| Mhp Md PLLC | PA | Urgent Care Clinic/Center | $0 | $6.5M |
| Plymouth Meeting Ambulatory Surgical Center LLC | PA | Ophthalmologic Surgery Clinic/Center | $1.3M | $0 |
| Harvey Fracht | PA | Ophthalmology Physician | $340.8K | $0 |
| Jeffrey Heebner | PA | Family Medicine Physician | $223.4K | $0 |
| Mohammad Farooq | PA | Physical Medicine & Rehabilitation Physician | $48.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.